Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TLZlIvPSEQvF2= NY\0RmpSOS12IHS= MV\EUXNQ Ml\F[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> MkfiNlU1QTB|OEO=
H1703 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL1c5czNjVizszN M17C[|EuPCCm MoPmSG1UVw>? NYrYWZZR\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? MV2yOVQ6ODN6Mx?=
HUVECs M{\3U2N6fG:2b4jpZ4l1gSCDc4PhfS=> MYCxNFAhdk1? MVKyOEBp MVTheJRmdnWjdHXzJJRp\SCjYoLv[4F1cX[nIHXm[oVkfHNib3[gZ4FtgWOxc3nuJI9vKF[UST3pcoR2[2WmIHP5eI91d3irY3n0fS=> MmDONlU1PTBzOE[=
APRE-19 NIPjc2RCeG:ydH;zbZMhSXO|YYm= MUO1JO69VQ>? M2jj[|I1KGh? M1nwZYFjd2yrc3jld{BHVFpvbXXkbYF1\WRicILvMZN2en[rdnHsM4FvfGlvYYDvdJRwe2m|IHHjeIl3cXS7 M2PT[FI2OzJ7NkG3
MDA-MB-231 M1XHe2Fxd3C2b4Ppd{BCe3OjeR?= MWKxxsDPxE4EoB?= NXy1Z5NiPDhiaB?= MX\EUXNQ NUPwWXZm\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKHS{ZXH0[YQhf2m2aDCyOUDPxE1ib3[gSlEhd3JiRkKgxsA> M2X1ZVI2OzByOUOy
MCF7 M2HRcWZ2dmO2aX;uJGF{e2G7 MkPNNVAxKG6P MUOyOEBp MnTm[YxqdWmwYYTld{BGOi2rbnT1Z4VlKEGURT3MeYMh[WO2aY\peJk> MonqNlUyPzJ3NUe=
HT-29  MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHzWW84OS53wrFCuW0> NGDJNHM6PiCq NYLaZod3\GWlcnXhd4V{KGOnbHyg[5Jwf3SqIIfobYNpKGOjbjDi[UBqdmirYnn0[YQh[nliS2nORS=> M2S4T|I2ODF{MUKz
MO59K  NEfsTG1EgXSxdH;4bYNqfHliQYPzZZk> MmnEOeKh|ryP MXu3JIQ> MoHKSG1UVw>? MYTlcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? MWSyOFk2OzV4MR?=
MO59J NHL5bWtEgXSxdH;4bYNqfHliQYPzZZk> NHW1fng2yqEQvF2= NHfHd3Y4KGR? MlHLSG1UVw>? NIXseFVmdmijbnPld{B1cGViY4n0c5RwgGmlaYT5JI9nKGW2b4Dvd4ll\SCxcjDjbZNxdGG2aX6= MnnxNlQ6PTN3NkG=
MO59K  M1nhUGFxd3C2b4Ppd{BCe3OjeR?= MlvPNVAh|ryP NHjOfnczPCCq NXzsdlNQTE2VTx?= M4LTXIlv[3KnYYPld{B1cGViRGPCJIxmfmWuIHnu[JVk\WRiYomg[ZRweG:|aXTlJI9zKGOrc4DsZZRqdg>? MXiyOFk2OzV4MR?=
MO59J NUnaWWVkSXCxcITvd4l{KEG|c3H5 MX[xNEDPxE1? M4jGWlI1KGh? NHn1cHZFVVOR NVv1R2NIcW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw MViyOFk2OzV4MR?=
HepG2 MWPGeY5kfGmxbjDBd5NigQ>? M1;5PVExOCCwTR?= NFfIeVUxNjViaB?= M1Lj[WROW09? NVnKbmht[myxY3vzJG1CNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NFjyUYMzPDh4M{O1NC=>
A549  NHLTXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fYNVMhyrWPwrC= MXqyJIg> M3zsTpN2eHC{ZYPz[ZMheGWvZYTy[Zhm\C2rbnT1Z4VlKEGtdDDhcoQhT1ONM98yJIFkfGm4YYTpc44tKFNvcHjhd4Uh[XK{ZYP0MEBk\WyuIHHwc5B1d3OrczDhcoQh[2G|cHHz[U0{KGGldHn2ZZRqd25? M1PVSFI1QDR5OE[z
A549  NV;nUHgxTnWwY4Tpc44hSXO|YYm= M1\ifFExyqEQvH5CpC=> NVLreJlIOTZiaB?= M{PMW2ROW09? MkjmcY9lfWyjdHXzJJRp\SCLQW[gdoVxdGmlYYTpc44h[W6mIHPheZNmeyC{ZYTlcpRqd25ib3[gUnAhcW5idHjlJI52[2yndYOu MnjNNlQ5ODJzMUG=
SK-N-LO MUXGeY5kfGmxbjDBd5NigQ>? M3nJeVExOCCwTR?= M4L2N|AvPSCq NXy3Spk{\GWlcnXhd4V{KHSqZTDzeIlufWyjboSg[YZn\WO2czDv[kBud3KyaHnu[UBwdiCDa4SgdIhwe3Cqb4L5cIF1cW:w MUGyOFY2PDZyNh?=
HL-60 NX7F[|B{TnWwY4Tpc44hSXO|YYm= NVu2OJNGOC5zwrFOwG0> NXzlPFRXPzJiaB?= NXWzbotJ[myxY3vzJIRie2G2aX7pZk1qdmS3Y3XkJINmdGxiZHnm[oVz\W62aXH0bY9v MoHmNlQ3ODd{N{O=
HepG2  NGm5fHFHfW6ldHnvckBCe3OjeR?= Mmf2NlAxKG6P MoPZNE42KGh? NV74cHhX[XS2ZX71ZZRmeyCIb4jPJJBpd3OyaH;yfYxifGmxbh?= NFLqN4czPDV|NUG5Ni=>
H520 M{\lfWZ2dmO2aX;uJGF{e2G7 NXv3dllFOTEEoN88US=> M13uclEhcA>? MmPQSG1UVw>? NVKzfld6\GWlcnXhd4V{KGOnbHz1cIFzKHCqb4PwbI8uSUuWIIDyc5RmcW5ibHX2[Yx{ MmD3NlQ1PDd7M{W=
H1975 NEXVb2dHfW6ldHnvckBCe3OjeR?= NV\NVFloOTEEoN88US=> NEe2d40yKGh? NYDB[HVZTE2VTx?= MYXk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= MnTnNlQ1PDd7M{W=
MG-63 NEG3bZdCeG:ydH;zbZMhSXO|YYm= NFixTm4yOCEEtV2= M3LNXVEzKGh? M{HBPYVvcGGwY3XzJGRRNWmwZIXj[YQh[XCxcITvd4l{ NYLqfYVEOjR|NUizNFE>
5637 NW[wOGZESXCxcITvd4l{KEG|c3H5 NYi4NllnOTEEoN88US=> NWnFZ4JTPDBibXnu NFvLS2Rz\X[ncoPld{BxOjGZQV[xJIV5eHKnc4Ppc44tKEOGSzDlfJBz\XO|aX;uMEBidmRiY3XscEBqdmirYnn0bY9vKGmwZIXj[YQh[nliZoXjc4ll[W5? MoXBNlQ{OzN6Nki=
HEK-293 MkDQSpVv[3Srb36gRZN{[Xl? NXXzfHdPOTVybl2= MlrVNVYhcA>? NYHYNIt1TE2VTx?= MlPN[IVkemWjc3XzJGNTXCCjY4Tpeol1gQ>? NG\2SpEzPDN{NEO2Oi=>
SW480  NXr2cZlJTnWwY4Tpc44hSXO|YYm= M4\3UFE2OG6P NELqdJMzOCCq MkXYSG1UVw>? NUL5TWRQemWmdXPld{Bk\WyudXzhdkBi[2O3bYXsZZRqd25ib3[g{tIu[2G2ZX7pci=> NHfrV|gzPDN{NEO2Oi=>
HepG2 MXPGeY5kfGmxbjDBd5NigQ>? NEn0VZkyODBibl2= MYSyOEBp NIrQZXJifHSnboXheIV{KHSqZTDjc4xwdmmnczDv[kB1cGVidIXtc5Ih[2WubIOge4l1cCC3cILl[5Vt[XSrb36gc4YhSWu2MR?= NYnTVpluOjR{OUe1NVA>
HCT 116  MVjGeY5kfGmxbjDBd5NigQ>? MljONVAxKG6P Mk\mNlQhcA>? MYfheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? NV;R[mNqOjR{OUe1NVA>
BEL/FU MoT2SpVv[3Srb36gRZN{[Xl? NFjIR48yKG2P Ml\vNlQhcA>? MUHk[YNz\WG|ZYOgdJJwfGWrbjDs[ZZmdHNib3[geIhmKFCLM1uvRYt1KHCjdHj3ZZk> NX7mNndzOjR{M{KwPVk>
Huh7  M2\3SWZ2dmO2aX;uJGF{e2G7 NIfBTHc{yqEQvF2= NUK0VXIzOSCq MVny[YR2[2W|IITo[UB3cXK3czDlcpRzgSCrboTvJJRp\SClZXzsdy=> M2DnVlI1OTh2MUm2
A-375 NGPpdpdCeG:ydH;zbZMhSXO|YYm= M3jkS|QwQCEQvF2= M4nJWFI1KGh? MoTT[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= MlvvNlQyOTNzN{O=
A-375-TS  M{i4TmFxd3C2b4Ppd{BCe3OjeR?= MmDrOE85KM7:TR?= NWnjXnFpOjRiaB?= MWrlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NWX1ZWZOOjRzMUOxO|M>
Mel-HO NUTKZlVmSXCxcITvd4l{KEG|c3H5 MYG0M|gh|ryP MkXYNlQhcA>? NWj5do1i\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MUWyOFEyOzF5Mx?=
Mel-HO-TS NFTtbGdCeG:ydH;zbZMhSXO|YYm= NIDnbVk1NzhizszN NUe1flE1OjRiaB?= NUjSe3dF\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MWKyOFEyOzF5Mx?=
MeWo M4n4bGFxd3C2b4Ppd{BCe3OjeR?= NVHFOG44PC96IN88US=> M1zCelI1KGh? NWDPUIxU\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> Mo\MNlQyOTNzN{O=
Mel-2a M2qxNGFxd3C2b4Ppd{BCe3OjeR?= MXG0M|gh|ryP M3zkc|I1KGh? M1fqRYVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MojFNlQyOTNzN{O=
MDA-MB-231 Mn3GSpVv[3Srb36gRZN{[Xl? MXGw5qCUPDByIH7N MonEOEBp M{\ucZN2eHC{ZYPz[ZMhSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1nsfVIzQTB4MkW5
MDA-MB-231 NGe5c|FHfW6ldHnvckBCe3OjeR?= MWK0NFAhdk1? MojvOEBp MVLk[YNz\WG|ZYOgUW1RNTliYX7kJGlNNThicILveIVqdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mlu2NlI6ODZ{NUm=
Jurkat MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfHNE4zPS1zLkK1JO69VQ>? NXnnV4hCOjRxNEigbC=> MmPqSG1UVw>? NGDib2NqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MoXLNVk4PTdzOEW=
Namalwa NEfBWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrGW2dlOC5{NT2xMlI2KM7:TR?= NHTtZVUzPC92ODDo MlfESG1UVw>? NE\WNotqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MWCxPVc2PzF6NR?=
Jurkat MVHBdI9xfG:|aYOgRZN{[Xl? MVewMlI2NTFwMkWg{txO Mnq2NlQwPDhiaB?= NXL0PG8xTE2VTx?= NIDPUmRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NHPlXmwyQTd3N{G4OS=>
Namalwa M2K2dmFxd3C2b4Ppd{BCe3OjeR?= NWS0bmQzOC5{NT2xMlI2KM7:TR?= MYOyOE81QCCq NHn2cWpFVVOR M37aTYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NXz6[m5lOTl5NUexPFU>
K562 M{C1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzLNlQhcA>? M2HpW2lEPTB;MkZCtVAvOTRibl2= NIK4SnQyQTZ4MkO2NS=>
SW1990 M2flfWZ2dmO2aX;uJGF{e2G7 M4LMNlAvODFvMTFOwG0> MlLUNUBp NUPjcJp4cW6qaXLpeJMhUEFvaX7keYNm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w M4XVNVE6PDZ7MEKw
RT112  NFmxc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWxNVDDqM7:TR?= MmPkNlQhcA>? M17aemROW09? NFHUN|dl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? Mm\NNVg4QDd6M{K=
MHG-U1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrpWWYyOMLizszN NEjL[5YzPCCq NVnpfJVnTE2VTx?= NEn6RnNl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? MYKxPFc5Pzh|Mh?=
SMMC-7721 NGnrT4dCeG:ydH;zbZMhSXO|YYm= NHjOdIkzODEEoH7N M3v2NlI1KGh? MVXpcoNz\WG|ZYOgR2hZNWmwZIXj[YQh[XCxcITvd4l{ MmfMNVc2PTdzOUG=
SMMC-7721 NVe3VFZKTnWwY4Tpc44hSXO|YYm= NHK0cFkzODEEoH7N MYKyOEBp MVH1dE1z\We3bHH0[ZMh|rJzLETHWFEh\XiycnXzd4lwdg>? MlvnNVc2PTdzOUG=
HeLa NYTGeIxlTnWwY4Tpc44hSXO|YYm= NFW4SIcyODEEoH7NxsA> NXTzbHFUOSCq M{fGfoFtfGW{czD0bIUhdW:{cHjvcI9ogSCxZjD0bIUhfHKjboPm[ZJzcW5icnXjfYNtcW6pIHPvcZBienSvZX70 NI[3SpYyPjh7MEmxOS=>
MRC5VI NY\iRoFzTnWwY4Tpc44hSXO|YYm= NU[wTlF7OTJwNTDtUS=> M2TB[|AvPSCq M{PqcGROW09? NGruPHVi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MU[xOlIzPzN7NB?=
AT5BIVA MUTGeY5kfGmxbjDBd5NigQ>? MlH5NVIvPSCvTR?= MnuyNE42KGh? M2TJXGROW09? Mn\BZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> NX;CXnU2OTZ{MkezPVQ>
M059J M175WWZ2dmO2aX;uJGF{e2G7 MWSxNk42KG2P MlPNNE42KGh? MkK2SG1UVw>? NIj2SYxi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MVKxOlIzPzN7NB?=
HeLa NVHweWliTnWwY4Tpc44hSXO|YYm= M2O0blEzNjVibV2= M4G0SVAvPSCq NIH1[5JFVVOR M4fWfIFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh MWOxOlIzPzN7NB?=
N2a M1vsRWFxd3C2b4Ppd{BCe3OjeR?= MluxNE4yNTFyIN88US=> Mnz2NkBp NH;NfohqdmS3Y3XzJIRm[3KnYYPl[EBk\WyuII\pZYJqdGm2eTDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= MXuxOVg1Ojd4Nx?=
Jurkat  MmjGT4lv[XOnIFHzd4F6 NFvLNY5KSzVyIH;mJFI1KG6P MXexOVY3PDVzOR?=

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5%DMSO+corn oil
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID